H.C. Wainwright adjusted its outlook on Cullinan Oncology Inc. (NASDAQ:CGEM), raising the price target to $33.00 from the previous $28.00 while maintaining a Buy rating on the company's shares.

The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted ...

REGENXBIO Inc. today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at ...

Inc. , (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has ...

Tuberculosis remains one of the top infectious disease killers worldwide, a challenge amplified by drug-resistant forms of the disease.

New options make TB treatment faster, safer, and more accessible. A major breakthrough in tuberculosis treatment has emerged: ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

University of Kentucky Markey Cancer Center researchers have discovered a promising new way to combat therapy-resistant ...

Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. have announced the successful outcome ...